Skip to main content

Carey Danis & Lowe Lawyers Examine the Link Between Actos and Bladder Cancer

By December 3, 2012March 15th, 2022Actos, Pharmaceutical litigation, Uncategorized

Published November 29, 2012 by PR Web

Carey Danis & Lowe Lawyers Examine the Link Between Actos and Bladder CancerSt. Louis, Missouri (PRWEB) November 29, 2012

November is American Diabetes Month and the pharmaceutical product liability lawyers at Carey Danis & Lowe are examining the relationship of Actos and bladder cancer. In recent months, the European Medicines Agency and the U.S Food and Drug Administration (FDA) have reviewed the safety of the drug and its potential to cause bladder cancer.

Based on these studies, Carey Danis & Lowe provides consultation to those who may have been harmed by Actos and may be entitled to compensation.

According to the European Medicines Agency, last fall the French Medicines Agency made the decision to discontinue prescribing medicines in France containing pioglitazone, such as Actos. The French Medicines Agency came to this resolution based off of a French epidemiological study.

This French study was undertaken by Caisse National d’Assurance Maladie, a French health insurance organization. The French epidemiological study was conducted during 2006 – 2009. From the data compiled during the French study, it became clear that there is a significant link between the use of Actos and the development of bladder cancer.

Following suit, health officials in Germany have advised German health care providers to stop writing prescriptions for Actos, specifically for new diabetes patients.

Like the European Medicines Agency, the U.S. Food and Drug Administration (FDA) is currently reviewing the safety of Actos in regards to the development of bladder cancer in patients prescribed with the diabetes drug. In this review process, the FDA is actively watching a study being conducted by Takeda Pharmaceuticals involving over 100,000 diabetes patients.

The manufacturer of Actos, Takeda Pharmaceuticals, is leading a 10-year cohort study involving patients in the Kaiser Permanente Northern California health plan. In the Takeda Pharmaceuticals and Kaiser Permanente Northern California study, a 5-year interim analysis of data was undergone, which revealed that, in patients who had taken Actos for more than one year, the researchers saw a 40% increased risk of the development of bladder cancer.

Patients who used Actos and developed bladder cancer may be entitled to compensation. Carey Danis & Lowe provides consultation to those patients who may have been harmed by Actos. Please contact our pharmaceutical lawyers to learn more and file a case.


[European Medicines Agency: Update on ongoing European review of pioglitazone–containing medicines.
FDA Drug Safety Communication: Ongoing Safety Review of Actos (pioglitazone) and Potential Increased Risk of Bladder Cancer After Two Years Exposure. FDA Web site. Accessed November 14, 2012.